Servier’s Novel Brain Tumor Drug Vorasidenib Due For Oral Explanation At EMA

 
• By Vibha Sharma

Servier is set to make its case before the European Medicines Agency for the EU-wide approval of its innovative therapy for Grade 2 IDH-mutant glioma.

Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Patients with Grade 2 IDH-mutant gliomas have few post-surgery options (Shutterstock)

More from EU CHMP

More from Geography